Skip to content

NYU Langone Health Headache Center Learning Migraine Self-Management Techniques Study

NYU Langone Health Headache Center Learning Migraine Self-Management Techniques Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06077812
Enrollment
50
Registered
2023-10-11
Start date
2023-11-27
Completion date
2024-12-10
Last updated
2024-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine

Keywords

Migraine, Self-Management, Headache, Behavioral Intervention

Brief summary

The investigators aim to determine the feasibility of a migraine self-management program.

Detailed description

Patients with migraine seen by neurologists/headache specialists within or affiliated with the NYU Langone Health system will be identified via electronic medical record system, or in person. The investigators will randomize 50 participants to an in-person migraine self-management protocol, or a remote migraine self-management protocol. The investigators will examine benefits through follow-up at 2, 4, and 6 month time points.

Interventions

BEHAVIORALRELAXaHEAD Smartphone App

Participants will receive access to the smartphone application RELAXaHEAD, which contains features for migraine self-management including a headache diary.

Participants will receive in-person training in migraine self-management techniques.

Participants will receive virtual training in migraine self-management techniques.

Sponsors

NYU Langone Health
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* English speaking. (At this time, the validated app is only available in English.) * 18-65 years of age * Meets International Classification of Headache Disorder (ICHD)-3 migraine criteria based on a headache specialist or neurologist * Headaches for ≥1 year * Has not begun a new migraine preventative medication in the last month * Agreement to not make any preventive medication changes from the time of trial start until 3 months after beginning the study (Note - Acute medications may be changed if needed. Changes in preventive and acute medication and the time initiated will be recorded to evaluate the potential for medication confounds) * 4-29 headache days a month (so the study includes those in whom the investigators typically offer preventive treatment \[\>4 headache days/month\] and those with more frequent migraines including chronic migraine \[15 days or more/month\] but exclude those with continuous headaches)

Exclusion criteria

* Diagnosis of Medication Overuse Headache (MOH) * Patients who have had Cognitive Behavioral Therapy, Biofeedback, or other Relaxation Therapy for migraine in the past year * Alcohol or other substance abuse as determined by self-report or prior documentation in the medical record * Current opioid or barbiturate use * PHQ-8 scores greater than 15, indicating a conservative score of moderately severe depressive symptoms based on the PHQ-9 (in this group, more intense psychological intervention targeted to the depression may be needed, as depression is a significant predictor of migraine chronification and people with migraine and comorbid depression are more likely to be refractory to migraine treatments and to develop medication overuse headache) * Unable or unwilling to follow a treatment program that relies on written and audio-taped materials * Coronary heart disease, heart attack, stroke, diabetes mellitus Type 1 or II * Pregnant (because hormonal fluctuations in pregnancy can affect migraine outcomes) * Other physical limitations which would prevent participating in the standard protocol of biofeedback being studied

Design outcomes

Primary

MeasureTime frameDescription
Number of In-Person Sessions Attended by Participants in the In-Person Migraine Self-Management ArmUp to Month 2
Number of Days of At-Home PracticeUp to Month 2
Satisfaction ScoresMonth 2Assessment of satisfaction with the intervention using a Likert scale from 1 to 5 with 1 being strongly disagree, and 5 being strongly agree; the total score is the response; higher scores indicate greater satisfaction with the intervention.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 2, 2026